Increased Transparency in Medicare Advantage and Drug Programs
This bill aims to increase transparency in Medicare Advantage (Part C) and prescription drug (Part D) programs. It requires insurance companies and drug managers to disclose detailed data on ownership, payments, and costs, helping citizens better understand how these programs operate and where their money goes.
Key points
Medicare Advantage organizations will need to disclose data on services, diagnoses, and risk scores, especially if they have ownership ties with providers.
Pharmacy benefit managers (PBMs) will be required to disclose details on drug prices, rebates, and fees, which should help assess drug costs.
All collected information will be publicly available, but without revealing sensitive data, to promote fair competition and informed citizen choices.
Expired
Citizen Poll